-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Debio-4326 in Central Precocious Puberty
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Debio-4326 in Central Precocious Puberty Drug Details: Debio-4226 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SQY-51 in Duchenne Muscular Dystrophy
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SQY-51 in Duchenne Muscular DystrophyDrug Details:SQY-51 is under development for the treatment of Duchenne muscular dystrophy....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLG-100 in Keratoconjunctivitis Sicca (Dry Eye)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.SLG-100 in Keratoconjunctivitis Sicca (Dry Eye)Drug Details:SLG-100 is under investigation for the treatment of keratoconjunctivitis sicca (dry...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Debio-4127 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Debio-4127 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug Details: Debio-4127 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Debio-4126 in Acromegaly
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Debio-4126 in Acromegaly Drug Details: Debio-4126 is under development for the treatment of gastroenteropancreatic neuroendocrine...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PRT-3645 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PRT-3645 in Non-Small Cell Lung Cancer Drug Details: PRT-3645 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Debio-4127 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Debio-4127 in Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET) Drug Details: Debio-4127 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CVN-766 in Anxiety Disorders
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CVN-766 in Anxiety Disorders Drug Details:CVN-766 is under development for the treatment of anxiety disorders, schizophrenia...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INS-068 in Type 2 Diabetes
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. INS-068 in Type 2 Diabetes Drug Details: INS-068 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Debio-4126 in Acromegaly
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Debio-4126 in Acromegaly Drug Details:Debio-4126 is under development for the treatment of gastroenteropancreatic neuroendocrine tumors and acromegaly....
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.